Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

A TRANSPLANT recipient has died of cancer after contracting the illness from his organ donor. The unnamed patient, 69, from Arizona underwent an organ transplant to treat his liver ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung ...

The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

After serving the public for nearly 30 years and fighting to keep drugs off the streets, former DEA agent Keith Martin is battling to stay healthy after a cancer diagnosis.